Ando, Kenju
Naito, Tateaki http://orcid.org/0000-0003-4047-2929
Hamauchi, Satoshi
Miura, Keita
Nishibori, Yuichiro
Tonsho, Ayumi
Matsuda, Suguru
Morita, Meiko
Sekikawa, Motoki
Doshita, Kosei
Kodama, Hiroaki
Yabe, Michitoshi
Morikawa, Noboru
Iida, Yuko
Mamesaya, Nobuaki
Kobayashi, Haruki
Ryo, Ko
Wakuda, Kazushige
Ono, Akira
Kenmotsu, Hirotsugu
Murakami, Haruyasu
Yamazaki, Kentaro
Takahashi, Toshiaki
Article History
Received: 11 January 2024
Accepted: 30 April 2024
First Online: 9 May 2024
Declarations
:
: Tateaki Naito received grants from Otsuka Pharmaceutical K. K. and Japan’s Agency for Medical Research and Development (AMED), and personal fees from Ono Pharmaceutical Co., Ltd., and Helsinn Healthcare SA outside of the submitted work. Keita Miura received personal fees from AstraZeneca, Chugai Pharmaceutical, and Taiho Pharmaceutical outside of the submitted work. Motoki Sekikawa received personal fees from Chugai Pharmaceutical Co. Ltd. and Takeda Pharmaceutical outside of the submitted work. Hiroaki Kodama received personal fees from Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K. K. outside of the submitted work. Nobuaki Mamesaya received grants and personal fees from Boehringer Ingelheim, and personal fees from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceuticals, MSD K. K., AstraZeneca K. K., and Ono Pharmaceutical Co., Ltd. outside of the submitted work. Haruki Kobayashi received personal fees from Eli Lilly K. K., Novartis Pharma K. K., Taiho Pharmaceutical., AstraZeneca K. K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, and Daiichi Sankyo Co. outside of the submitted work. Ko Ryo received grants and personal fees from MSD K. K. and AstraZeneca K.K., and personal fees from Taiho Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., Eli Lilly K. K., Ono Pharmaceutical, Daiichi Sankyo, and Takeda, outside of the submitted work. Kazushige Wakuda received grants and personal fees from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., MSD K. K., Daiichi Sankyo Co., Ltd., and grants from Novartis Pharma K. K.; AbbVie, AMGEN, and Dizal Pharma, and personal fees from Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly K. K., Ono Pharmaceutical, Janssen Pharmaceutical K. K., Takeda Pharmaceutical, and Nihon Kayaku outside of the submitted work. Akira Ono received personal fees from AstraZeneca K. K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Indica Laboratories outside of the submitted work. Hirotsugu Kenmotsu received personal fees from AMGEN, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Daiichi-Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Taiho Pharmaceuticals, Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., MSD K. K., and Pfizer, and grants and personal fees from AstraZeneca K. K., Novartis Pharma K. K., Ono Pharmaceutical Co., Ltd., and Eli Lily K. K., and grants from Loxo Oncology, outside of the submitted work. Haruyasu Murakami received grants and personal fees from AstraZeneca K. K., Takeda Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Chugai Pharmaceutical Co. Ltd., and Taiho Pharmaceutical, grants from AbbVie and IQvia, Bayer, and personal fees from Amgen, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Japan, MSD K. K., Pfizer Inc., Novartis Pharma K. K., Eli Lilly Japan K. K., Eisai, and Nihon Kayaku, outside of the submitted work. Toshiaki Takahashi received grants and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K. K., MSD, Pfizer Japan Inc., and Amgen Inc., personal fees from Ono Pharmaceutical Co., Ltd., BMS Japan, Takeda Pharmaceuticals Co., and Novartis You, and grants from Merck Biopharma Co., Ltd., Janssen Pharmaceutical K. K., and AnHeart Therapeutics Inc. outside of the submitted work. The remaining authors declare no conflict of interest.